MFOLFOXIRI + PANITUMUMAB VERSUS FOLFOXIRI AS FIRST-LINE TREATMENT IN PATIENTS WITH RAS WILD- -TYPE METASTATIC COLORECTAL CANCER M(CRC): A RANDOMIZED PHASE II VOLFI TRIAL OF THE AIO (AIO-KRK0109)
Michael Geissler, Jorge Riera-Knorrenschild, Andrea Tannapfel, Jobst Greeve, Axel Florschütz, Swen Wessendorf, Thomas Seufferlein, Stephan Kanzler, Swantje Held, Volker Heinemann, Anke C. Reinacher-Schick, Uwe Marc Martens
Klinikum Esslingen, Department of Hematology/Oncology, Esslingen, Germany
Universitätsklinik Marburg, Marburg, Germany; Pathologisches Institut der Ruhr
Meeting: 2018 ASCO Annual Meeting Track: Gastrointestinal (Colorectal) Cancer Abstract number: 3509 Citation: J Clin Oncol 36, 2018 (suppl; abstr 3509) Authors: Michael Geissler, Jorge Riera-Knorrenschild, Andrea Tannapfel, Jobst Greeve, Axel Florschütz, Swen Wessendorf, Thomas Seufferlein, Stephan Kanzler, Swantje Held, Volker Heinemann, Anke C. Reinacher-Schick, Uwe Marc Martens; Klinikum Esslingen, Department...